Risk Factors Update Summary
- Products may not gain market acceptance, impacting results. Need to build commercial capabilities.
- Need to develop workforce to educate physicians and pharmacists for product adoption.
- Potential impact of new legislation limiting insulin copays to $35/month starting in 2023.
- Impact of healthcare reform measures on the pharmaceutical industry, including price negotiations and cost controls.
- Increased need for compliance with federal regulations, including FDA inspections and cGMP requirements.
- Potential impact of financial industry adverse events on business operations and financial condition.
- Increased focus on cybersecurity risks, including cyberattacks and data privacy laws.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=899460&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.